The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation—implications for preventative …
Background aims Although cytomegalovirus (CMV) infection after allogeneic stem cell
transplantation (SCT) is rarely fatal, the management of CMV by pre-emptive medication for
viral reactivation has toxicity and carries a financial burden. New strategies to prevent CMV
reactivation with vaccines and antiviral T cells may represent an advance over pre-emptive
strategies but have yet to be justified in terms of transplantation outcome and cost. Methods
We compared outcomes and post-transplantation treatment cost in 44 patients who never …
transplantation (SCT) is rarely fatal, the management of CMV by pre-emptive medication for
viral reactivation has toxicity and carries a financial burden. New strategies to prevent CMV
reactivation with vaccines and antiviral T cells may represent an advance over pre-emptive
strategies but have yet to be justified in terms of transplantation outcome and cost. Methods
We compared outcomes and post-transplantation treatment cost in 44 patients who never …
